Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia.

Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia. Abstract Text:

The involvement of specific pathways mediated through muscarinic receptor activity has been widely implicated in schizophrenia. Extensive pharmacological evidence supports the systems role in mediating antipsychotic drug efficacy, while mounting physiological evidence demonstrates the presence of significant alterations to normal muscarinic receptor integrity in the disorder. The mechanisms that facilitate the systems involvement and their magnitude, however, remain poorly understood. We have proposed that alterations to normal muscarinic receptor expression exist in schizophrenia, and that these significantly influence the physiological changes often reported for the system amongst patients. In this study, we investigate this potential, and have selected to examine the muscarinic 1 receptor, which constitutes a major target for antipsychotic action and plays a conspicuous role in those regions central to the disorders pathophysiology. Using relative gene quantification, we measured post-mortem levels of steady-state cortical muscarinic 1 receptor cDNA in patients (N = 20) and unaffected controls (N = 20), and examined group differences in expression levels. Commensurate with our hypothesis, we observed significant reductions in muscarinic 1 receptor cDNA in our patient sample (F(1,37) = 4.73, P = 0.036) and have estimated this to constitute a 28% decrease compared to the control subjects (95% CI from 2 to 47%). These results provide evidence in support of altered muscarinic 1 receptor expression in schizophrenia, though further work is needed to corroborate these findings.

Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: American journal of medical genetics. Part B, Neur

VOLUME: 119B

Page Numbers: 2-6

Journal Abbreviation: Am. J. Med. Genet. B Neuropsyc

ISSN: 1552-4841

DAY: 15

MONTH: May

YEAR: 2003

Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101235742

Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia. Keywords Mesh Terms:

KEYWORDS: Schizophrenia

MESH TERMS: metabolism

Chemical & Substance for Abstract: Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia. Information

Substance Name: Receptor, Muscarinic M1

Registry Number: 0

Grant and Affiliation Information for Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia.

AFFILIATION: Section of Clinical Neuropharmacology, Department of Psychological Medicine, Institute of Psychiatry, De Crespigny Park, London, England, UK. sphadtm@iop.kcl.ac.uk

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Am J Med Genet B Neuropsychiat

REFSOURCE: Am J Med Genet B Neuropsychiatr Genet. 2

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia Related Publications

• A faith-based intervention for cocaine-dependent Black women.
• An analytical examination of muscle force estimations using optimization techniques.
• Biological determinants of difficult to treat patients with schizophrenia.
• Cardiac alert: decreasing door-to-balloon time for ST elevation myocardial infarction.
• Caudate regional cerebral blood flow in obsessive-compulsive disorder, panic disorder and healthy controls on single photon emission computerised tomography.
• Coupling reactions of bromoalkynes with imidazoles mediated by copper salts: synthesis of novel N-alkynylimidazoles.
• Enediynes from aza-enediynes: C,N-dialkynyl imines undergo both aza-Bergman rearrangement and conversion to enediynes and fumaronitriles.
• Identification of the adduct between a 4-Aza-3-ene-1,6-diyne and DNA using electrospray ionization mass spectrometry.
• Musculoskeletal demands of progressions for the longswing on high bar.
• Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: structure and degradation pathways.
• Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia.
• Schizophrenic auditory hallucinations are associated with increased regional cerebral blood flow during verbal memory activation in a study using single photon emission computed tomography.
• Serotonergic polymorphisms and psychotic disorders in populations from North Spain.
• Simian Virus 40 Large T-Antigen G-Quadruplex DNA Helicase Inhibition by G-Quadruplex DNA-Interactive Agents.
• Some aspects of coronary atherosclerosis and its sequelae.
• Substance abuse treatment providers' beliefs and objections regarding contingency management: implications for dissemination.
• Synthesis, metal ion binding, and biological evaluation of new anticancer 2-(2'-hydroxyphenyl)benzoxazole analogs of UK-1.